Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States - Breast Cancer Research and Treatment
Source : https://link.springer.com/article/10.1007/s10549-022-06845-4
Purpose Delaying chemotherapy remains a vital goal in therapeutic management of HR+/HER2- metastatic breast cancer (MBC). However, recent reports continue to highlight substantially high chemotherapy utilization in earlier therapy lines....
Conclusions: This population-based study illustrates that chemotherapy utilization in earlier therapy lines for HR /HER2– MBC declined steadily between 2010 and 2019. These declines were significantly accelerated by the introduction of CDK4/6 therapy class in 2015, notably in the second- and third-line settings.
-
Albert Dekker3yrCK4/6 ar effective but for me they are intermediary between the traditional hormonal therapy and traditional cytotoxic agents
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE) - Breast Cancer Research
Source : https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-022-01587-z
Background KRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + P) versus docetaxel + carboplatin + trastuzumab + pertuzumab (TCH + P) in patients with HER2-positive, stage II-III breast cancer. We investigated the association of biomarkers with...
Conclusions: Although our biomarker analysis did not identify a subgroup of patients that benefited from neoadjuvant T-DM1 P versus TCH P, the data revealed that patients with higher HER2 amplification/expression and immune marker levels had improved response irrespective of treatment arm. These analyses confirm the role of HER2...
-
Albert Dekker3yrMakes sense
Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials - Breast Cancer
Source : https://link.springer.com/article/10.1007/s12282-017-0770-3
To compare the addition of targeted agents to fulvestrant with fulvestrant alone in hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy; a meta-analysis of all relevant randomized controlled...
Conclusions:Combining targeted agents with fulvestrant showed benefit but with increased toxicity in patients with advanced breast cancer compared with fulvestrant alone. Biomarkers for treatment optimization are lacking. The CD4/6 and PI3K/m-TOR pathways merit further investigation.
-
Albert Dekker3yrfulvestrant IM or new oral alternatives could be easily combinable with other agents. The bigger question is if those agents would perform as well without Faslodex and if there is Show More
Aditya Bardia on Elacestrant vs Standard-of-Care Endocrine Therapy in ER-Positive HER2-Negative Breast Cancer - The ASCO Post
Endocrine therapy with a CDK4/6 inhibitor is the preferred first line treatment for patients with hormone receptor positive metastatic breast cancer, but patients eventually have disease progression. Endocrine resistance could...
Conclusions: There's a clinical trial called ELEVATE, which would look at Elacestrant in combination with other targeted therapies such as PI3 kinase inhibitor, mTOR inhibitor, CDK4/6 inhibitor. The ELEVATE trial would look at Elacestrant based combinations for patients with hormone receptor positive metastatic breast cancer.
-
Albert Dekker3yrit depends on selection of patients and reasons for their endocrine resistance
Therapeutic drug monitoring in breast cancer therapy - LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum
Source : https://www.sciencedirect.com/science/article/abs/pii/S073170852200632X?via=ihub
Quantification of CDK4/6 inhibitors by semi-automated sample preparation and LC-MS/MS. * Method validation according to FDA including long-term stability up to one year. * TDM of oral tumor therapeutics in...
Conclusions: This novel semi-automated LC-MS/MS method covering all previously approved CDK4/6 inhibitors as well as the similarly pharmacologically active metabolites in human serum simultaneously was developed for potential future use in routine analysis in order to improve
-
Albert Dekker3yrhow to get it and how much that would cost?
-
Breast Cancer Connect3yrKey Points • Source: Journal of Pharmaceutical and Biomedical Analysis • Relevance: “The aim of the present work was to establish a semi-automated liquid-chromatography tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of Show More